STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…

Biosimilars 363

Biosimilars Drug Pricing Documentation Pharmaceutical Companies 363

STAT

NOVEMBER 1, 2023

A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising drug prices to controversial heights — agreed to pay up to $50 million to settle allegations of purposely underpaying Medicaid rebates. Department of Justice.

Drug Pricing 298

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 298

RX Note

APRIL 16, 2023

Why Drug Prices Are Rising? Newly developed drugs can be expensive to produce. During patent exclusivity, prices are set higher to offset the high research and development cost (up to billions of dollars). Additionally, many middlemen are involved in the drug supply chain , each taking a cut of the profits.

Drug Pricing 40

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 40

Viseven

JANUARY 13, 2023

Evaluation of drug efficiency on a dedicated market is a complex process that requires HEOR experts to measure multiple indicators to understand the actual market value of the product. So what do exactly HEOR experts do for the pharmaceutical companies and what HEOR-collected data is used for? What is HEOR Data?

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Dosage Drug Pricing 40

pharmaphorum

MAY 14, 2021

Long headquartered in London, the EU drug regulator is now severed from the country both physically and systematically, with its base now in Amsterdam and the UK now assessing drugs through its own regulatory agency, MHRA. This additional effort could lead to poorer patient access. “It

Drug Pricing 59

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 59

pharmaphorum

JUNE 10, 2021

Jesse Mendelsohn explores pharma’s priorities on pricing, profits and progress post-Covid. It goes without saying that if pharmaceutical companies are not profitable, they will not survive. The truth about rising drug prices is more nuanced and merits exploration. The Big Misconception.

Drug Pricing 105

Drug Pricing Vaccines Pharmaceutical Companies Pharmaceutical Companies 105